GlassScriptPhysician profile
Mehdi Poorkay
NPI 1649265059
$80,924.41
in general payments reported to CMS, 2019-2025
31 companies · $355 in 2025
The $355 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $51K · 2020: $22K · 2021: $5,955 · 2022: $137 · 2023: $595 · 2024: $217 · 2025: $355.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,142 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,141.98 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $27,413.34 | 2019-2025 | Wegovy, Ozempic |
| Astrazeneca Pharmaceuticals LP | $20,319.43 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12,343.45 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $9,769.14 | 2019-2020 | |
| Lilly USA, LLC | $5,931.01 | 2019-2020 | |
| Tandem Diabetes Care, INC. | $2,300.00 | 2020 | |
| Amgen INC. | $468.64 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $378.42 | 2019-2025 | |
| Insulet Corporation | $256.69 | 2019-2024 | Omnipod |
| Shire North American Group INC | $206.79 | 2019 | |
| Abbott Laboratories | $202.06 | 2019-2025 | Freestyle Libre 3 |
| Medtronic, INC. | $200.12 | 2021-2023 | Minimed 780g |
| Amryt Pharma Holdings LTD | $139.08 | 2023 | Mycapssa |
| Regeneron Healthcare Solutions, INC. | $134.50 | 2019 | |
| Esperion Therapeutics, INC. | $124.97 | 2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Minimed, INC. | $115.30 | 2019-2020 | |
| Clarus Therapeutics INC. | $109.62 | 2021 | |
| Antares Pharma, INC. | $72.56 | 2019-2020 | |
| Dexcom, INC. | $63.08 | 2019-2022 | |
| Ibsa Pharma INC. | $62.07 | 2019-2020 | |
| Pfizer INC. | $60.14 | 2023-2024 | |
| Currax Pharmaceuticals LLC | $59.91 | 2019-2023 | Nexletol, Contrave, Nexlizet |
| Abbvie INC. | $51.03 | 2019 | |
| Amarin Pharma, INC. | $31.44 | 2019-2020 | |
| Radius Health, INC. | $22.45 | 2019-2020 | |
| Endo Pharmaceuticals INC. | $19.89 | 2019 | |
| Senseonics, Incorporated | $17.00 | 2019 | |
| Corcept Therapeutics | $14.19 | 2019 | |
| Horizon Therapeutics Plc | $13.60 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.87 | 2019 | |
| Nalpropion Pharmaceuticals LLC | $11.62 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mehdi Poorkay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.